ADHD - Inattentive Type Completed Phase 2 Trials for Methylphenidate (DB00422)

Also known as: ADHD Predominantly Inattentive Type / ADHD, Predominantly Inattentive Type / Attention Deficit Disorder / Attention Deficit Disorder Patients / ADD / Attention Deficit Disorder (ADD) / Attention Deficit Disorders / Attention Deficit Disorder Without Hyperactivity / Attention-deficit hyperactivity disorder, predominantly inattentive type / Attention deficit disorder of childhood without mention of hyperactivity / Attention deficit hyperactivity disorder, predominantly inattentive type (disorder) / Attention deficit disorder of childhood / Child attention deficit disorder (disorder) / Androstenedione / Androstenedione (substance) / Add - dosing instruction fragment (qualifier value) / Attention-deficit hyperactivity disorder, unspecified type / Attention deficit hyperactivity disorder / Attention deficit hyperactivity disorder, predominantly hyperactive impulsive type (disorder) / Hyperactive child syndrome / Attention deficit disorder of childhood with hyperactivity / ADHD / ADHD, predominantly hyperactive-impulsive type / Attention deficit/hyperactivity disorder NOS / Attention deficit/hyperactivity disorder / Attention deficit-hyperactivity disorder / Attention-deficit hyperactivity disorders / Attention Deficit Disorder with Hyperactivity / Attention deficit hyperactivity disorder (disorder) / Hyperkinetic syndrome of childhood / Hyperkinetic syndrome / Syndrome hyperkinetic

IndicationStatusPhase
DBCOND0060357 (ADHD - Inattentive Type)Completed2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT02225106Dopamine Receptor Imaging to Predict Response to Stimulant Therapy in Chronic TBITreatment